A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Clinical trial NCT04847596 · COMPLETED
Trial details
- NCT number
- NCT04847596
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-05-21
- Primary completion
- 2022-02-18
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.